

Jonathan Macdonald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7299860/publications.pdf>

Version: 2024-02-01

23
papers

4,689
citations

933264

10
h-index

996849

15
g-index

24
all docs

24
docs citations

24
times ranked

10858
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i> , The, 2021, 397, 99-111.	6.3	3,887
2	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	6.1	233
3	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	6.1	153
4	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	3.7	111
5	Negative capsule endoscopy in patients with obscure GI bleeding predicts low rebleeding rates. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 1122-1127.	0.5	98
6	Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease: new insights into dietary disease triggers. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 935-947.	1.9	49
7	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	0.6	39
8	Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1111-1120.	0.6	36
9	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	3.7	23
10	Small Bowel Lymphangiectasia and Angiodysplasia. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 610-614.	1.1	15
11	Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease. <i>Nutrients</i> , 2021, 13, 2899.	1.7	11
12	The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2090485.	1.2	9
13	Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2021, 12, 345-347.	0.9	8
14	Muscle deficits with normal bone microarchitecture and geometry in young adults with well-controlled childhood-onset Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1497-1506.	0.8	7
15	Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2022, 13, 77-81.	0.9	2
16	PTH-133...herapeutic drug monitoring supports clinical decision making when employed before and after biosimilar infliximab switching. , 2019, , .		1
17	Whipple's disease: historical insights and contemporary perspectives. <i>Gastrointestinal Nursing</i> , 2011, 9, 34-39.	0.0	0
18	PWE-045...Vedolizumab results in reduced hospitalisation and steroid use over 1-year: results from the scottish vedolizumab cohort. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
19	PTH-132â€¦High rates of clinical response are maintained after switching from originator to biosimilar infliximab. , 2019, , .		0
20	P151â€¦Anti-drug antibodies to Infliximab: a comparison of free anti-drug antibody measurement. , 2021, , .		0
21	O47â€¦The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers. , 2021, , .		0
22	P275â€¦Analysis of exclusive enteral nutrition formulas in Crohnâ€™s disease â€“ new insights into dietary triggers. , 2021, , .		0
23	PMO-40â€¦Comparison of the Partial Mayo and PUCAI severity scores in Ulcerative Colitis. , 2021, , .		0